Bicycle Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCYC research report →
Companywww.bicycletherapeutics.com
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4.
- CEO
- Kevin Lee
- IPO
- 2019
- Employees
- 305
- HQ
- Cambridge, GB
Price Chart
Valuation
- Market Cap
- $309.60M
- P/E
- -1.42
- P/S
- 4.88
- P/B
- 0.56
- EV/EBITDA
- 1.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -11.86%
- Op Margin
- -381.75%
- Net Margin
- -344.95%
- ROE
- -35.74%
- ROIC
- -40.17%
Growth & Income
- Revenue
- $72.59M · 105.77%
- Net Income
- $-218,960,000 · -29.54%
- EPS
- $-3.16 · -8.59%
- Op Income
- $-247,718,000
- FCF YoY
- -52.21%
Performance & Tape
- 52W High
- $9.36
- 52W Low
- $4.24
- 50D MA
- $4.82
- 200D MA
- $6.42
- Beta
- 1.65
- Avg Volume
- 456.33K
Get TickerSpark's AI analysis on BCYC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 26 | Hannay Michael Charles Ferguson | sell | 1,521 |
| Apr 6, 26 | Hannay Michael Charles Ferguson | sell | 251 |
| Apr 2, 26 | Thompson Travis Alvin | sell | 799 |
| Apr 6, 26 | Thompson Travis Alvin | sell | 102 |
| Apr 2, 26 | Perry Jennifer Scott | sell | 1,038 |
| Apr 6, 26 | Perry Jennifer Scott | sell | 37 |
| Apr 6, 26 | Perry Jennifer Scott | sell | 333 |
| Apr 2, 26 | Lee Kevin | sell | 5,967 |
| Apr 6, 26 | Lee Kevin | sell | 1,716 |
| Apr 2, 26 | Skynner Michael | sell | 1,879 |
Our BCYC Coverage
We haven't published any research on BCYC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BCYC Report →